Aims: Experimental and epidemiological studies reported controversial data on the role of omentin in type 2 diabetes and cardiovascular diseases. This study aimed to characterise the impact of omentin on the secretome of human adipocytes to analyse the enrichment of these proteins in metabolic and cellular signalling pathways underlying its physiological function.
Omentin is predominantly secreted by the stromal vascular fraction of visceral adipose tissue. 1 Currently available studies controversially discuss whether omentin exerts a protective or detrimental role in type 2 diabetes (T2D) and cardiovascular diseases (CVD).
Cross-sectional studies found decreased circulating levels of omentin in obese compared with lean individuals and lower omentin levels in patients with T2D compared with glucose tolerant people. 2, 3 In a cross-sectional analysis of the Cooperative Health Research in the Region of Augsburg (KORA) F4 study, we observed that omentin did not differ between individuals ranging from normal glucose tolerance to T2D. 4 However, higher circulating omentin was inversely associated with multiple risk factors for T2D and CVD. [2] [3] [4] [5] These findings were supported by in vitro studies showing that omentin increased Akt phosphorylation and insulin-stimulated glucose uptake in human adipocytes. 1 With respect to CVD, circulating omentin was decreased in patients with coronary artery disease 6, 7 and appeared to have a protective role in patients with ischaemic stroke. 8, 9 In line, administration of omentin in mice reduced tissue damage after ischaemia/reperfusion 10 and delayed the development of aortic atherosclerotic lesions with reduced vascular inflammation.
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In contrast with the findings from cross-sectional and experimental studies, the prospective analysis within the KORA F4/FF4 cohort indicated that higher circulating omentin is associated with a higher risk of T2D. 12 This is in line with a prospective analysis within the European Prospective Investigation into Cancer and Nutrition-Potsdam study demonstrating an increased omentin-related diabetes risk among people with high adiponectin levels. 13 In the same cohort, circulating omentin was associated with an increased risk of stroke, 14 and another prospective study reported high circulating omentin levels as predictor of cardiovascular events. 15 Data on the inflammatory properties of omentin are limited to very few biomarkers. Circulating omentin associated inversely with interleukin-6 (IL-6), 3, 16 tumour necrosis factor (TNF)α, 3 and C-reactive protein, 5, 13, 16 and positively with adiponectin. 2, 4, 13 On the cellular level, omentin reduced TNFα-induced inflammation in human endothelial cells and murine smooth muscle cells by inhibiting several kinases and transcription factors of inflammatory pathways. 17, 18 Taken together, the mechanism by which omentin affects metabolic and inflammatory processes in cardiometabolic diseases is incompletely understood. Therefore, the aims of the study were (1) to investigate the impact of omentin on the secretome of proteins in differentiated human adipocytes, (2) to analyse the overrepresentation of the omentin-regulated proteins in well-characterised metabolic and cell signalling pathways, and (3) to identify other potential upstream activators of omentin-regulated proteins.
| MATERIAL AND METHODS

| Cultivation and treatment of human adipocytes
Primary human preadipocytes isolated from subcutaneous adipose tissue from five donors without diabetes were purchased from PromoCell (Heidelberg, Germany) and Lonza (Basel, Switzerland). 19 Approval by an ethics committee was not required. Human preadipocytes were cultured in preadipocyte growth medium (PromoCell) containing 0.05 mL/mL fetal calf serum (FCS), 0.004 mg/mL endothelial cell growth supplement, 10 ng/mL epidermal growth factor, 1 μg/mL hydrocortisone, and 90 μg/mL heparin until 100% confluency. Then, preadipocytes were differentiated in preadipocyte differentiation medium (PromoCell) containing 8 μg/ mL D-biotin, 0.5 μg/mL insulin, 400 ng/mL dexamethasone, 44 μg/ mL 3-isobutyl-1-methylxanthine, 9 ng/mL L-thyroxine, and 3 μg/mL ciglitazone. After 3 days, differentiation medium was replaced by adipocyte nutrition medium (PromoCell) containing 0.03 mL/mL FCS,
8 μg/mL D-biotin, 0.5 μg/mL insulin, and 400 ng/mL dexamethasone.
The adipocytes were differentiated for further 11 days. At day 14 of differentiation, adipocytes were cultivated in adipocyte nutrition medium without insulin and FCS for 4 hours and then treated with 500 or 2000 ng/mL omentin for 24 hours with untreated cells as controls. After this incubation time, adipocyte supernatant was collected and centrifuged for 10 minutes at 1800 × g at 4°C. Then, 800 μl were transferred in a new tube and stored at -80°C until the proteomics analysis. The aforementioned omentin concentrations were selected based on our analysis of serum samples from the KORA F4 study. 12 The concentration of 500 ng/mL is close to the median level in a non-diabetic population, whereas 2000 ng/mL is close to the highest levels found in this population, but most likely closer to local levels found in adipose tissue.
| Quantitative mass spectrometry in dataindependent acquisition mode
Six hundred microlitres of each supernatant was proteolysed with a modified filter aided sample preparation procedure. 20 Spectra were recorded in data-independent acquisition mode [23] [24] [25] with the following parameters: MS spectra from 300 to 1650 m/z were recorded at 120 000 resolution with an automatic gain control target of 3e6 and a maximum injection time of 120 ms. Data-independent acquisition windows were selected based on previous data-dependent acquisition runs, with a scan resolution of 30 000, an automatic gain control target of 3e6, and a collision energy of 28. The recorded raw files were analysed using the Spectronaut 10.0 software (BIOGNOSYS) 26 with an in-house human database spectral library which was generated using Proteome Discoverer 
| RESULTS
The supernatant of omentin-treated and untreated differentiated human adipocytes contained 3493 proteins. Of these proteins, 275
proteins were regulated by 500 ng/mL omentin and 317 proteins by 2000 ng/mL omentin. There was an overlap of 140 proteins between both omentin concentrations, which are listed in Suppl. Table 1 . These proteins are localised either in the cytoplasm, extracellular space, plasma membrane, or nucleus (Suppl. Table 1 ). Suppl. Figure 1 depicts the dose-dependent effect of omentin on the secretion of these 140
proteins.
3.1 | Impact of omentin on protein secretion Table 1 shows the top 20 of the most upregulated and the top 20 of the most downregulated proteins by omentin (see Suppl. Table 1 
| Canonical pathways
Omentin-regulated proteins were overrepresented in seven canonical pathways (B-H P < 0.05). By far, the strongest association was observed for eukaryotic initiation factor (EIF)2 signalling (Table 2 ). (Table 3 ).
| Potential upstream regulators
| DISCUSSION
The main findings of this study were (1) The fold-change in expression for the listed proteins refers to adipocytes treated with 2000 ng/mL omentin for 24 h compared with untreated adipocytes. The expression P-value was calculated by a paired t-test.
| Anti-inflammatory TNFAIP-6 as most regulated protein upon omentin treatment
Tumour necrosis factor-inducible gene 6 protein is only produced upon exposure to inflammatory factors and has been described as protein with anti-inflammatory and tissue-protective properties. 28 It acts as an endogenous inhibitor of inflammatory processes and represents a component of a negative feedback loop. 28 Interestingly, one antiinflammatory action of TNFAIP6 is the regulation of chemokine function. 28 TNFAIP6 binds to multiple chemokines and interacts with them through their glycosaminoglycan-binding site, which leads to the inhibition of their binding to glycosaminoglycans and endothelial cell surfaces. 28 In this comprehensive proteomics study, the chemokine 
| Omentin-regulated proteins associated with inflammation, T2D, and comorbidities
It is noteworthy that further proteins that are among the most omentin-regulated proteins in adipocyte supernatant have been implicated in the pathogenesis of T2D. One protein is the adipokine SFRP4 which belongs to the Sfrp family, the largest family of wingless (Wnt)
inhibitors. 32 Higher levels of SFRP4 were associated with a higher risk of T2D and associated with higher fasting glucose, and lower insulin sensitivity index and disposition index. 33 CTSS is another protein which has been upregulated by omentin.
This protein has been reported to be higher in diabetic rats compared to healthy ones and correlated with blood glucose levels. 34 In addition, CTSS is upregulated in adipose tissue from obese patients, and its inhibition led to a decrease of lipid content and adipocyte marker expression 34 indicating that it might affect both glucose metabolism and adipocyte function.
Two other proteins are known to be involved in endothelial dysfunction: ICAM-1 and vascular cell adhesion protein 1 (VCAM-1) belong to the Ig superfamily of cell membrane proteins. 35 The release of the soluble form of ICAM-1 (sICAM-1) and VCAM-1 (sVCAM-1) is related to inflammatory and infectious diseases. 35 Higher levels of both proteins are associated with increased risk for cardiovascular events. 36 Interestingly, we found that sICAM-1 and sVCAM-1 are also released by adipocytes in response to omentin. Although it is not known why adipocytes produce the soluble forms of these proteins and if they represent mere risk markers of CVD or rather contribute to its development, it should be noted that this finding agrees with the aforementioned positive association between omentin and cardiovascular risk in prospective studies.
LIMS1 has been described to be upregulated by the pro-inflammatory TNFα. 37 We found that also omentin is able to upregulate LIMS1 in adipocytes. One important role of LIMS1 is the regulation of the function of renal tubules 37 suggesting a potential omentinmediated crosstalk with kidneys and diabetes-associated nephropathy.
With respect to potential omentin-induced signalling pathways,
we identified an omentin-stimulated upregulation of the NFκB activating protein (NKAP), which activates NFκB. It has been proposed that PSMB3, USP32, PSMA7, UBE3B, HSPA13, PSMA1, UBE2I
The analysis was based on proteins which were differentially secreted upon treatment with 2000 ng/mL omentin. P-values for the canonical pathways were calculated by Fisher's exact test and corrected for multiple testing using the Benjamini-Hochberg method (B-H P-value).
EIF, eukaryotic initiation factor; p70S6K, 70-kDa ribosomal S6 kinase.
Abbreviations of omentin-regulated proteins are explained in Suppl. Table 1 . B4GALT1, B4GALT5, BDP1, MMP2, PTX3
The identification of potential upstream activators was based on differentially regulated proteins by omentin treatment with 2000 ng/mL in differentiated human adipocytes supernatant. The P-values were calculated by Fisher's exact test. The molecule type was filtered according to the following categories: complex, cytokine, enzyme, growth factor, kinase, phosphatase, transcription regulator, translation regulator, transmembrane receptor, and transporter.
Abbreviations: Cg, choriogonadotropin; CXCL8, C-X-C motif chemokine ligand 8; ETS1, ETS proto-oncogene 1; IFNG, interferon gamma; IKBKB, inhibitor of kappaB kinase beta; IL1A, interleukin-1 alpha; IL1B, interleukin-1 beta; IL6, interleukin-6; IL17A, interleukin-17 alpha; MAPK8, mitogen-activated protein kinase 8; MIF, macrophage migration inhibitory factor; NFkB (complex), nuclear factor kappa B; NOS2, nitric oxide synthase 2; OSM, oncostatin M; PTGS2, prostaglandin-endoperoxide synthase 2; SMARCA4, SMI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily 5, member 4; SP1, Sp1 transcription factor; SPP1, secreted phosphoprotein 1; STAT1, signal transducer and activator of transcription 1; STAT3, signal transducer and activator of transcription 3; TGFB1, transforming growth factor beta 1; TNF, tumour necrosis factor; TLR3, toll-like receptor 3; TLR4, toll-like receptor 4.
Abbreviations of omentin-regulated proteins are explained by Suppl. Table 1 .
NKAP mediates TNF-and IL-1-induced NFκB activation. 38 Our data show that NKAP is also released into the supernatant of omentintreated adipocytes. Again, we can exclude that NKAP is released because of cell death as we performed cell viability tests that did not indicate any differences between untreated and omentin-treated adipocytes (data not shown).
Activated NFκB signalling is associated with the action of the inflammasome. Interestingly, Lys-63-specific deubiquitinase BRCC36
(BRCC3), which also belongs to the strongest upregulated proteins, has been identified as deubiquitinating enzyme of NLR family pyrin domain containing 3 (NLRP3) and thereby regulates the activity of the inflammasome. 39 This in turn supports the pro-inflammatory action of omentin.
| Omentin-regulated proteins associated with general cellular functions
Most of the top 20 of the most-downregulated proteins by omentin also play a role in the regulation of cellular processes. Several proteins are involved in protein synthesis such as the eukaryotic translation initiation factor 3 subunit D (EIF3D), and the eIF2 alpha kinase activator homologue GCN1. 40, 41 In obesity, stress kinases are able to inhibit the general protein synthesis and thereby affect endoplasmatic reticulum (ER) function, which in turn has a harmful impact on inflammation and metabolism. 42 This finding indicates that omentin might cause cellular stress in differentiated human adipocytes.
The most interesting protein in this group was selenoprotein P (SEPP1) which has anti-oxidant activity. Secreted SEPP1 is suggested to bind to proteoglycans on the vascular endothelial surface and thereby protects against oxidative damage. 43 However, several studies reported a detrimental effect of SEPP1 on insulin sensitivity. 43, 44 Nevertheless, this finding might be explained by a dysregulated carbohydrate metabolism in T2D because SEPP1 is regulated by insulin and glucose levels. 44 Further studies are necessary to evaluate the role of adipocyte-derived selenoprotein on adipocytes and/or other cell types relevant for cardiometabolic diseases.
4.4 | Omentin-regulated secretory proteins were overrepresented in pathways relevant for cellular stress, a pro-inflammatory environment, and crosstalk between organs acute-phase response leads to a higher release of pro-inflammatory factors which are able to activate the complement system. 45 Apart from immune defence, the complement system is also involved in metabolic and inflammatory processes in adipose tissue. 46 The omentin-regulated complement components C3, complement factors B and H have pro-inflammatory properties and are associated with insulin resistance and T2D. 46, 47 Based on our data, we conclude that omentin directly induced the acute-phase response and components of the complement system which in turn might contribute to the observed pro-inflammatory condition in adipocytes and thus promote the development of insulin resistance and T2D.
The pathway designated Inhibition of the Matrix Metalloproteases contains matrix metalloproteases (MMPs), as the omentin-regulated MMP2, which are able to regulate the bioavailability and activity of FIGURE 1 Proposed physiological role of omentin in differentiated human adipocytes chemokines. 48 The tissue inhibitors of metalloproteases (TIMP) tightly control the synthesis and degradation of MMPs. 49 The omentin-regulated TIMP1 is known as an adipocyte-secreted protein upregulated by pro-inflammatory cytokines such as IL-1β, IL-6, and TNFα mediated by NFκB. 50, 51 Our data suggest that omentin-regulated MMP2 might contribute to the pro-inflammatory environment and its regulator TIMP1 might be regulated by omentin through activation of NFκB in adipocytes.
Another inflammation-related canonical pathway is the Protein Ubiquitination Pathway. The ubiquitin-proteasome system is known as activator of NFκB because its activity depends on the ubiquination of IκB followed by proteasomal degradation. 52 Therefore, these data again support the potential importance of NFκB in omentin action in adipocytes.
Our study also revealed Hepatic Fibrosis/Hepatic Stellate Cell Activation as pathway in which omentin-affected proteins are overrepresented. It is known that proteins that are released from adipocytes are also able to control hepatic inflammation and fibrosis. 53 In our dataset, predominantly VCAM-1 and ICAM-1 as well as MMP2 and TIMP1 were upregulated by omentin and involved in this pathway.
Serum levels of VCAM-1 and ICAM-1 are predictors of hepatic fibrosis and hepatocellular carcinoma risk, respectively. 54, 55 Interestingly, the transcriptional activation of TIMP-1 and MMP-2 is important for the pathogenesis of liver fibrosis. 53 The potential link between these proteins and pathways should be investigated by omentin treatment of hepatocytes or co-culture experiments of adipose tissue and hepatocytes to characterise the potential role of omentin in the cross-talk between both tissues.
| Potential upstream regulators of omentinregulated proteins are predominantly NFκB activators
The in silico characterisation of potential upstream regulators of the omentin-regulated secretion pattern identified several molecular mechanisms by which omentin might regulate protein secretion and thereby affect the development of T2D and CVD in human studies.
Most of the potential upstream activators of the proteins that are differentially regulated by omentin are pro-inflammatory cytokines.
Interestingly, the most activated upstream cytokines IL-1β and TNFα regulate the activity of NFκB, and all three classes of MAPK (JNK, ERK1/2, and p38 MAPK). 56, 57 The cytokine IFN-γ is known to activate the transcription factor signal transducer and activator of transcription (STAT) 1 via the receptor-associated Janus kinases JAK 1 and 2 leading to the regulation of alternative cytokine signalling pathways. In addition, IFN-γ is also described to activate ERK1/2 and has been implicated in the vascular proliferative responses in atherosclerosis. 58 The cytokine IL-6 activates STAT3 through JAKs and thereby induces the transcription of target genes and regulates lipid and glucose metabolism as well as immune responses. 59 The transmembrane receptors toll-like receptors (TLR)3 and 4 also regulate NFκB activity, 56 and Sp1 transcription factor (SP1) regulates transcription factor p65 (RelA) which is involved in NFκB heterodimer formation. 60 In addition, NFκB and its inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB) were themselves identified as potential upstream regulators. Therefore, this study argues for a central role of NFκB in the pro-inflammatory action of omentin.
| Strengths and limitations
One important strength of our study is the use of primary human differentiated adipocytes. In addition, we used physiological concentrations of omentin and performed a comprehensive analysis of the almost 3500 secreted proteins induced by omentin using proteomics analysis.
Regarding limitations, it should be noted that we used commercially available preadipocytes which we differentiated into mature adipocytes. Although the preadipocytes had been purified by magnetic beads or cultivation in medium which impeded the adherence of other cell types, a low level of contamination with, eg, immune or endothelial cells cannot be excluded as in all in vitro assays using primary cells isolated from adipose tissue. Additionally, differentiation into mature adipocytes never reaches 100%, so that our cultures may also have contained a low percentage of preadipocytes, which however was the same for each treatment group for any given cell donor. We found that omentin-regulated proteins are localised either in the cytoplasm, extracellular space, plasma membrane, or nucleus. According to a colorimetric cell viability test (WST-8), no differences following omentin treatment were observed compared with control (data are not shown), so that it is unlikely that cell death due to omentin treatment contributed to the effects described here. However, we cannot exclude that a low level of cell death in all treatment groups led to the release of proteins that are usually localised within the cell.
| CONCLUSION
Omentin increased the secretion of a series of proteins, most importantly TNFAIP6, from differentiated human adipocytes. This protein is only expressed in response to inflammatory stimuli and has antiinflammatory activities which may suggest an inhibitory feedback loop to omentin release. However, the majority of omentin-regulated proteins and their potential upstream regulators pointed towards proinflammatory effects of omentin that may be mediated primarily by NFκB. Pathway analysis supported a role of omentin in inflammation, cellular stress, and inter-organ cross-talk, which may explain the positive associations between omentin and cardiometabolic risk in prospective studies in humans.
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